Caplin Point Laboratories' record shows unqualified audit opinions for FY2025-26 and a promoter group that holds 70.57% of shares with zero pledge. The issues that matter sit in three places: receivables are stretching without any provisioning, profits are not fully converting to cash, and a large loan to a subsidiary keeps growing. The rest of the record is a mix of disclosed, quantified items that are being pursued or are routine.
Key findings
- Receivables are rising faster than revenue with zero impairment allowances
Major- Receivables days rose from 95 in FY2019-20 to 138 in FY2025-26, while revenue grew from ₹863.20 crore to ₹2,187 crore over the same period. The company provided no allowance for impairment on trade receivables in any year from FY2019-20 through FY2023-24, citing a historical trend of "no credit loss". Management attributes the stretch to government and tender-based sales it calls "highly secure". - Profits convert to operating cash at only \~0.62x EBITDA over ten years
Major- Cumulative CFO of ₹2,345 crore against cumulative EBITDA of ₹3,810 crore gives a CFO/EBITDA ratio of 0.62x. CFO/PAT conversion was 0.81x in FY26 and 0.80x in FY25. The company is funding a ₹1,000 crore capex plan from internal accruals, with about ₹500 crore still to be incurred in the next 18-24 months. - A ₹267.54 crore unsecured loan to subsidiary Caplin Steriles has fluctuated since FY22
Major- The loan for capex stood at ₹267.54 crore as at March 31, 2026, up from ₹245.80 crore in FY25, ₹262 crore in FY24, ₹156 crore in FY23, and ₹39.75 crore in FY22. It carries interest at 11.00% p.a. in FY26, payable with monthly rests, with principal repayable over 5 years after a moratorium. Shareholders passed an ordinary resolution approving a fresh material RPT for Caplin Steriles on September 30, 2024 with 99.39% votes in favour. - Insurance claim in litigation; property title transfer pending
Minor- Machinery damaged by Michaung Cyclone floods in December 2023 was declared a total loss, but insurers denied the claim citing address discrepancies. The claim receivable was reduced to ₹27.37 crore as at March 31, 2026, with legal proceedings ongoing. A property purchased via e-auction from Punjab National Bank in FY2020-21 still lacked title transfer as at March 31, 2026. - Promoter family consolidates board control in FY2026
Minor- The Chairman's two sons were appointed Non-Executive Directors and Vice-Chairmen effective November 5, 2025, making three related directors on the board. One son draws USD 25,000 per month from a step-down subsidiary in Guatemala. The CFO was appointed Whole-Time Director for two years from August 12, 2026, alongside his CFO role. - Unqualified opinions with recurring audit-trail and title gaps
Minor- Brahmayya & Co. issued unqualified opinions on FY2025-26 standalone and consolidated financials, dated May 14, 2026. A Key Audit Matter on revenue recognition was communicated in the FY2025-26 consolidated report. The audit trail feature was not enabled at the database level for payroll and ledger software in FY2025-26. - A layered offshore structure routes Latin American acquisitions through Hong Kong
Minor- The group has 5 subsidiaries and 9 step-down subsidiaries, with material ones including Caplin Steriles Limited, Guatemala, Hong Kong, and Nicaragua. Caplin Point Far East Limited (Hong Kong) acquired Neoethicals Chile SpA on April 1, 2025, and executed a Share Purchase Agreement for Triwin Pharma S.A. DE C.V. (Mexico) on June 3, 2025, with completion to follow within 30 days. The injectables business sits in Caplin Steriles, which has external investors holding Compulsorily Convertible Preference Shares. - Statutory auditor rotated after completing its maximum tenure
Clean- CNGSN & Associates LLP held office through FY2022-23, with its term ending at the 32nd AGM in September 2023 after serving an initial one-year term, a three-year term, a five-year term, and a one-year extension. Shareholders approved Brahmayya & Co as the new auditor on September 21, 2023, with 56,087,663 votes in favour (99.98%) and 10,240 against out of 56,097,903 total votes cast. No auditor resignation occurred in FY2021-22, FY2022-23, FY2024-25, or FY2025-26.
What to watch
- AGM votes. The 35th AGM in September 2026 will vote on the MD's re-appointment, the Chairman's continuation beyond age 75, and the CFO's Whole-Time Director appointment.
- El Salvador tender collection. The CFO said receivables from a big tender won in El Salvador would be collected by end of Q2 FY2027.
- Insurance claim litigation. The Caplin Steriles claim is before the Hon'ble High Court of Madras as of the FY2025-26 Annual Report.
- SARFAESI title transfer. Title transfer for the ₹17.38 crore property purchased from Punjab National Bank was pending as at March 31, 2026.
- Exchange cautionary letter. A confidential cautionary letter from NSE and BSE was dated March 28, 2025.
Bottom line: This is a profitable parent with a promoter group fully invested. The risk is that reported profits are not fully converting to cash, and the gap is showing up in receivables that carry no impairment provision. The growing loan to Caplin Steriles and the subsidiary's external preference shareholders mean the group's cash is not all in one place. Watch the El Salvador collection and the AGM votes.